- Home
- Publications
- Publication Search
- Publication Details
Title
Chemically Programmed Bispecific Antibodies in Diabody Format
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 291, Issue 37, Pages 19661-19673
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2016-07-22
DOI
10.1074/jbc.m116.745588
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
- (2016) Min Zhu et al. CLINICAL PHARMACOKINETICS
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
- (2016) Eugene A Zhukovsky et al. CURRENT OPINION IN IMMUNOLOGY
- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
- (2015) Ignace B. Vergote et al. CANCER AND METASTASIS REVIEWS
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects
- (2015) Yuan Liu et al. MOLECULAR PHARMACEUTICS
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
- (2015) Gurunadh R. Chichili et al. Science Translational Medicine
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
- (2015) Jens Schreiner et al. OncoImmunology
- Chemically programmed antibodies
- (2014) Christoph Rader TRENDS IN BIOTECHNOLOGY
- Recruiting Cytotoxic T Cells to Folate-Receptor-Positive Cancer Cells
- (2013) Sumith A. Kularatne et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Bispecific small molecule-antibody conjugate targeting prostate cancer
- (2013) C. H. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
- (2012) B. A. Kamen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical translation of folate receptor-targeted therapeutics
- (2012) Lesheng Teng et al. Expert Opinion on Drug Delivery
- Chemically Programmed Bispecific Antibodies That Recruit and Activate T Cells
- (2012) Huiting Cui et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
- (2012) Patricia M. LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- DARTs take aim at BiTEs
- (2011) C. Rader BLOOD
- Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
- (2011) P. A. Moore et al. BLOOD
- TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects
- (2011) M. Sommariva et al. CANCER RESEARCH
- Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
- (2011) H. Huang et al. CLINICAL CANCER RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics
- (2010) Ulrich Wuellner et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Transiently redirected T cells for adoptive transfer
- (2010) Hilde Almåsbak et al. CYTOTHERAPY
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Folate-Targeted Therapies for Cancer
- (2010) Wei Xia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
- (2010) Syd Johnson et al. JOURNAL OF MOLECULAR BIOLOGY
- Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics
- (2010) Stephen Thompson et al. mAbs
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Folate-targeted therapeutic and imaging agents for cancer
- (2009) Philip Stewart Low et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Direct Observation of an Enamine Intermediate in Amine Catalysis
- (2009) Xueyong Zhu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy
- (2008) M. De Cesare et al. CLINICAL CANCER RESEARCH
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now